

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/008387 A1

(51) International Patent Classification⁷: **G06K 19/077**,
G08B 21/02, A61B 5/00, A61M 37/00, B01L 3/00, B65B
57/20

Battelle Boulevard, PO Box 999, Richland, WA 99352
(US).

(21) International Application Number:
PCT/US2003/022074

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARRENDER, Curt** [US/US]; 18410 Butterfield Blvd., Suite 150, Morgan Hill, CA 95037 (US). **STEWART, Roger** [US/US]; 18410 Butterfield Blvd., Suite 150, Morgan Hill, CA 95037 (US).

(22) International Filing Date: 14 July 2003 (14.07.2003)

(25) Filing Language: English

(74) Agents: **TARLETON, Russell, E.** et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).


(26) Publication Language: English

(30) Priority Data:
10/196,487 15 July 2002 (15.07.2002) US

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,

[Continued on next page]

(54) Title: SYSTEM FOR TRACKING MEDICAL DEVICES



(57) Abstract: A system for monitoring medical devices, such as pharmaceuticals and prescriptions, is provided that utilizes Radio-Frequency Identification (RFID) techniques. The system includes an RFID tag associated with the medical device, the tag programmed with information about the device, such as data about the manufacture, distribution, and sale thereof. The system further includes a reader that interrogates the tag and updates a database regarding the condition of the tag. The information in the tag can be revised by the reader or by an associated detector as the condition of the medical device changes, such as its location, sale, use, shelf life, and disposal. The system can also be configured to enable financial transactions, such as between an insurer and a provider or between a financial institution and a medical facility.

WO 2004/008387 A1



SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

SYSTEM FOR TRACKING MEDICAL DEVICES

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention pertains to the tagging and monitoring of
5 medical devices, and moreover to remote detection of the distribution, sale,
delivery, and condition of medical devices, particularly pharmaceuticals.

Description of the Related Art

Pharmaceuticals and their containers, related medical items, such
as syringes, IV's, catheters, and dressings are used in both in-patient and out-
10 patient treatment. Because these medical devices are expensive, involve rapid
turnover, and are frequently controlled by government regulation, they must be
carefully monitored.

The manufacture and distribution of these medical devices
requires careful tracking to ensure timely delivery, continuous checking of the
15 inventory to determine its status, including the shelf life of drugs, and careful
tracking to monitor the location of controlled substances and to ensure timely
delivery. Unauthorized use and theft of controlled substances results not only in
financial loss but contributes to societal ills resulting from addiction to controlled
substances.

20 There is also a need to ensure that physicians and pharmacists
are authorized to prescribe and deliver drugs to authorized patients. It is also
important to ensure that the correct medication and dosage is provided to a
patient, and that it is opened and used in accordance with the prescribed terms.
Physicians and pharmacists are liable for errors in prescriptions, and patients
25 can be injured by the misuse of medications.

In addition to the foregoing, there is the need for correct reporting
of the sale and distribution of these medical items to insurance companies and
regulatory agencies to ensure that financial transactions are timely completed

and payment is made under the correct insurance policy, and that government regulatory requirements are being met. This requires a large amount of data be acquired by medical professionals and institutions and reported to the respective agencies and insurers. In addition, patients require such data for
5 providing payment instructions to financial institutions and insurers. Consequently, there is a need for a system that provides continual automated reporting of the foregoing information in a manner that is non-intrusive yet reliable and accurate.

BRIEF SUMMARY OF THE INVENTION

10 The present invention is directed to a method and system for tracking medical devices, which includes pharmaceuticals, a prescription for pharmaceuticals, their containers, and devices for administering the same, including patches, swabs, syringes, IVs, catheters, dressings, and the like. In accordance with one embodiment of the invention, a Radio Frequency
15 Identification (RFID) system is provided that includes an RFID tag adapted to be attached to a medical device, or as a part of the device or inside the device, and having stored thereon, or configured to point to, information about the device and configured to transmit the information upon interrogation.

In accordance with another aspect of the foregoing embodiment
20 of the invention, the information stored on the tag can include information about an authorized user, such as the patient, manufacturer, including date of manufacture and shipping history, as well as information about the device itself, including its status as to location, times and frequency of usage, and remaining shelf life.

25 In accordance with yet another aspect of the foregoing embodiment, the tag is configured to be updated such that the stored information remains current as the condition of the device changes.

In accordance with still yet another aspect of the foregoing embodiment, the tag is configured to store and transmit transactional
30 information, such as payment authorization.

In accordance with another embodiment of the invention, an RFID system for tracking medical devices is provided that includes an RFID tag adapted to be attached to a medical device and having stored thereon information about the device and to transmit the information upon interrogation thereof; and a reader configured to interrogate the tag and to receive the transmitted information from the tag. The tag may be powered by the interrogation signal from the reader, from ambient energy, or from a combination thereof.

In accordance with yet another embodiment of the invention, an RFID apparatus is provided that includes a container for pharmaceuticals; an RFID tag attached to the container; and a device associated with the container and coupled to the tag to provide information to the tag as to the status of the container. Status can include opening of the container, breaking of a conductive seal on the container, as well as the location of the container with respect to geographic reference points or movement of the container.

In accordance with yet another embodiment of the invention, an RFID reader is provided for querying medical devices in pharmacies, doctors' offices, hospitals, homes, and in the field for continual monitoring of device.

In accordance with another aspect of the foregoing embodiment, the reader is configured to link the device monitoring to a database for access by regulatory agencies, financial institutions, medical institutions, and the like. In addition to providing data, the reader is configured to initiate the transfer of funds from one party to another and to authorize other financial transactions.

In accordance with still yet a further aspect of the present invention, a medical prescription system is provided that includes a container for storing the prescription; and a tag associated with the container and configured with information regarding the prescription. In one embodiment the tag is configured with information regarding at least one of patient history, insurance, patient identification, hospital information, dosage, biometrics, government regulation, and physician information.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

The foregoing and other features and advantages of the present invention will be more readily appreciated as the same become better understood from the following detailed description when taken in conjunction with the accompanying drawings, wherein:

Figure 1 is a block diagram of a system for tracking medical devices formed in accordance with the present invention;

Figure 2 is a more detailed diagram of a tag and reader formed in accordance with the present invention; and

Figures 3A-3D illustrate a container with a detector and a tag circuit formed in accordance with the present invention.

DETAILED DESCRIPTION OF THE INVENTION

Referring initially to Figure 1, shown therein is a block diagram representation of a system 10 for tagging and tracking a medical device 12. It is to be understood that the medical device 12 can be a pharmaceutical, such as a controlled substance, or a related medical item such as a container for the pharmaceutical, a syringe or IV for administering the pharmaceutical, a catheter, a medical implant, swab, patch, dressing, orthotic, and other medical supplies and equipment. While a preferred embodiment of the invention will be illustrated and described with respect to pharmaceuticals, it is to be understood that the invention will have broader applications.

Also shown in Figure 1 is a block representation of the manufacturer 14 of the medical device 12 and the inventory 16 where newly manufactured devices are stored. One possible distribution path is to a pharmacy 18 from which the medical device 12 is delivered to the consumer or patient 20. The solid lines with arrowheads 22 indicate possible distribution channels for the medical device 12. One possible distribution channel is from the manufacturer's inventory 16 to a medical institution 24, such as a hospital or doctor's office. The inventory 16 may also represent a warehouse maintained

by a distributor at a local or regional facility. The medical device 12 may also be distributed to the prescriber 26, such as a physician or clinic.

Also shown in Figure 1 are an insurance provider 28, government agency 30, and financial institution 32. The dotted lines 34 with arrowheads
5 indicate communication links between each of the entities listed above and the medical device 12 in accordance with the system and method of the present invention, which is described in more detail below. It is to be further understood that while the system 10 illustrated in Figure 1 shows interaction among each of the entities and further between each entity and the medical device, it is to be
10 understood that the system can be applied between only one entity and a medical device or the system can be applied to two or more entities with the medical device 12 or with multiple medical devices.

Communication with the medical device 12 takes place between an RFID tag 36 associated with the medical device 12 and an RFID reader 38
15 associated with each of the entities, as shown.

Referring next to Figure 2, shown therein is a simplified diagram of the system 10 involving the reader 38 and the tag 36, both having an antenna 40. The reader 38 is configured to transmit an interrogation signal 42 that is received by the tag 36. In response thereto, the tag returns a modulated
20 reflected signal 44 containing data or other information stored in the tag 36.

Communication using a passive (non-powered) device where an interrogation signal is modulated and reflected by the passive device is known and will not be described in detail herein. Briefly, backscatter communications involve selectively changing and reflecting the interrogation signal 42 by the tag
25 36. For example, modulating the radar cross section of a target causes energy reflected off the target to contain the information in its phase or amplitude modulation. The reader receiving the reflected energy is usually the device that has supplied the original energy required for this communication, and the reader 38 is configured to extract the data in the modulated reflected signal 44
30 by comparing the modulated reflected signal 44 to the original interrogation signal 42.

In RFID technology, commercial backscatter communications systems utilize microwave frequencies. In certain applications, the transceiver antenna 40 is a component of both a transceiver and a decoder in the reader 38, which makes the reader 38 an interrogator that can be configured either as
5 a hand-held or fixed-mount device. The reader 38 emits the interrogation signal 42 in a range from one inch to one hundred feet or more, depending upon its power input and the radio frequency used. When an RFID tag 36 passes through the interrogation signal 42, the tag 36 detects the signal 42 and is activated. Data encoded in the tag 36 is then transmitted through reflection by
10 the modulated signal 44 through the antenna 40 and to the reader 38 for subsequent processing.

When an RFID tag 36 is powered by the interrogation signal, it is referred to as a passive device because it derives the energy needed for operation from the radio frequency energy beamed at it. The tag 36 rectifies
15 the field and dynamically changes the reflective characteristics of the tag antenna 40, creating a change in reflectivity that is seen at the reader 38. In contrast, a battery half empowered semi-passive RFID tag operates in a like fashion, modulating its RF cross section in order to reflect a delta to the reader 38 to develop a communication link. In this case, the battery is the source of
20 the tag's operational power. In an active RFID tag, a transmitter is used to create its own radio frequency energy powered by the battery.

Both the tag 36 and the reader 38 of the disclosed embodiments of the invention may be formed using known techniques, including the fluidic self-assembly process disclosed in U.S. Patent Nos. 6,291,896; 6,281,038; and
25 6,274,508, all of which are incorporated by reference herein in their entirety.

The tag 36 is configured to store, or to point to, information regarding the medical device 12 and its manufacture, distribution, sale, use, disposal after use, and payment thereof. This information can consist of data regarding the manufacture of the device 12, including the manufacturer, date of
30 manufacture, shelf life, shipping date, lot number, as well as data regarding the inspection, inventory, and distribution of the device 12.

At each location, the reader 38 interrogates the tag 36 to identify the tag. Information about the tag is then updated on a database that is either associated with the reader 38, that is located at a remote location and coupled to the reader 38, or both. A prescribing physician 26 can provide information
5 about the intended user of the device 12, such as a patient 20, and this information can be matched to the interrogated tag for verification and authentication. A verified user can then authorize payment from a financial institution 32 or insurer 28 to the correct party, such as the prescribing physician 26, the pharmacy 18, or a medical institution 24. In addition, governmental
10 agencies 30 can utilize the information for tracking the device 12, especially in the case of controlled substances.

The tag used in conjunction with the medical device may be configured to enable programming of the tag to update the status of its condition. For example, the tag can be programmed by the manufacturer at the
15 time of delivery to a pharmacy with information regarding the manufacture and delivery of the medical device. The pharmacy may then program the tag or use another tag to store information regarding the contents of the medical device and its condition, and in addition the device can be programmed with information regarding the specific prescription, the user, the prescriber, as well
20 as payment and insurance information. This information can also be provided by a hospital, long-term care facility, or the prescribing physician as desired.

Ideally, the tag 36 is configured to be written to by the reader 38 in order to update the information regarding the tag. For example, when a tagged device 12 is transferred to a patient 20 by the pharmacy 18, the information is
25 updated as to the location of the tag, date of sale, identity of the patient 38 by a reader, and financial information, such as insurance coverage and payment.

The condition of the tag 36 may also be monitored by using a device that detects a changed condition of the device 12. This can include, but is not limited to, detecting whether the device 12 has moved, where it is
30 presently located, if and when it has been opened, and how many times it has been opened, and how much of the useful life of the device 12 has expired or

remains. The detection of the changed condition can be accomplished in a variety of ways, including physical switches, Doppler radar, and the like.

Referring to Figures 3A-3D, shown therein is an embodiment of the invention wherein a container 70 has an integrally-formed detector circuit 72 that is electrically coupled to the RFID tag 36. As shown in Figure 3A, the container 70 includes a receptacle 74 having side walls 76 and a closed bottom 78 defining a hollow interior 80 that is accessed via an opening 82, which is covered by a cap 84. Pharmaceuticals, such as pills 86, are stored in the interior 80 of the receptacle 74. The cap 84 may be threadably engaged with the receptacle 74 or snapped thereon in a well-known manner that will not be described in detail herein. The RFID circuit 36 is integrally formed in the cap 84 and includes an antenna 40 that for purposes of illustration is shown extending from the cap 84, but is preferably integrally formed with the RFID tag 36 as part of the cap 84 and is generally not visible to a user.

Negative and positive leads 88, 90, respectively, extend from inputs to the RFID tag 36 to first and second arcuate metal segments 92, 94, respectively. The segments 92, 94 are shown in more detail in Figure 3B. Ideally, the metal segments 92, 94 are embedded or formed in association with the cap 84.

Also shown in Figure 3 are corresponding first and second terminals 96, 98 formed in the rim 100 of the receptacle 74. More particularly, the first and second plates 96, 98 are formed from a single metal ring 102 that circumscribes the opening 82 to the receptacle 84. As shown in Figure 3C, the first plate 96 forms a capacitive element C1 with the first metal segment 92; and the second metal plate 98 forms a capacitive element C2 with the second metal segment 94.

The first and second plates 96, 98 form a common plate via the metal ring 102 to couple the first and second capacitive elements C1, C2 in series, as shown in Figure 3D. For example, if the first and second capacitive elements C1, C2 were each 20 pF, the equivalent capacitance would be 0.1 pF, which is shown schematically in Figure 3D.

When the cap 84 is removed from the receptacle 74, the capacitive circuit is broken. This is detected by the RFID tag 36, causing a change in its reflective characteristics. This in turn alters the backscattering characteristics of the tag 36, which is interpreted by a reader as a change in the
5 condition of the container 70, *i.e.*, that the cap has been removed.

Although a particular embodiment of the detection device has been illustrated and described, with respect to the detection device, it is to be understood that other methods may be used as known to those skilled in the art, including use of a resistive element, a conductor, an antenna, or other
10 element that affects the backscattering characteristics of the tag 36. Simplicity, lightweight, and low cost are key factors in designing and implementing the detector. In addition, other elements can be provided, including an LED display for providing a visual indicator to a user of the status of the medical device, including the number of times the cap 70 has been removed, the remaining life
15 of the prescription drug 86 or the expired portion of the life of the prescription drug 86, and a warning as to the condition of either the prescribed drug 86 or the container 70. Alternatively or in combination with the foregoing, an audible device may be incorporated into the container 70 to provide an aural form of communication, such as might be useful to the visually impaired. The foregoing
20 devices are readily commercial available and will not be illustrated and described herein. The source of power for such devices can be a small power cell incorporated into the container 70 or ambient energy received via the antenna 40 on the RFID tag 36, or energy from an interrogation signal sent from a remote reader.

25 Movement of the container 70 can also be detected utilizing quadrature null techniques implemented in the RFID monitoring system.

A timer circuit of known construction can be employed to provide information to both the tag 36 and the display as to the life of the prescription drug 86.

30 While a container 70 has been described as having a lid 84 on a receptacle 74, it is to be understood that containers in the form of blister packs

may be used where a tag is embodied in the blister pack. In one form, the tag can be rendered inoperational at the time the blister pack is opened or the backscatter modulation characteristics of the tag can be modified by opening the blister pack.

5 In accordance with a further embodiment of the invention, the system can be programmed to initiate financial transactions, such as the transfer of funds for the medical device. This can include authorization by verifying the identity of the user, availability of insurance coverage or funds in a bank account, and the legitimacy of the prescription from the prescribing
10 physician. Payment can be triggered by electronic debiting when the medical device is scanned at a register or when the device is physically removed from the facility or when a seal is broken or when usage has commenced. Payments can also include payment of taxes to the appropriate government agency as well as reporting on the condition of the medical device, such as its location and
15 usage.

 All of the information described above can be linked via a remote database. Such a database can be accessed via the Internet, a local intranet, such as in a hospital, or in a doctor's office or a patient's home office. Readers in each of the facilities can be linked to the Internet and the present condition of
20 the medical device is automatically monitored and reported without need for input from a patient.

 While representative embodiments of the invention have been illustrated and described, it is to be understood that various changes may be made therein without departing from the spirit and scope of the invention.
25 Hence, the invention is to be limited only by the scope of the claims that follow and the equivalents thereof.

 All of the above U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the
30 Application Data Sheet, are incorporated herein by reference, in their entirety.

CLAIMS

1. An apparatus for tracking a medical device, comprising:
a Radio Frequency Identification (RFID) tag adapted for attachment to the medical device and having stored thereon information about the medical device and configured to transmit the information upon interrogation.
2. The apparatus of claim 1 wherein the RFID tag has stored thereon information about at least one of a cost of the medical device, insurance coverage for the medical device, government regulation pertaining to the medical device, cost of the medical device, the user of the medical device, the manufacturer of the medical device, the manufacture of the medical device, and a distributor of the medical device.
3. The apparatus of claim 1 wherein the RFID tag comprises a sensor configured to monitor at least one condition of the medical device and to update the stored information as the condition of the medical device changes.
4. The apparatus of claim 1, further comprising a reader configured to interrogate the RFID tag and to receive and store the information transmitted by the RFID tag.
5. A monitoring system, comprising:
a medical device; and
a Radio Frequency Identification (RFID) tag adapted for attachment to the medical device and having stored thereon information about the medical device and configured to transmit the information upon interrogation.

6. The system of claim 5 wherein the RFID tag has stored thereon information about at least one of a cost of the medical device, insurance coverage for the medical device, government regulation pertaining to the medical device, cost of the medical device, a user of the medical device, a manufacturer of the medical device, manufacture of the medical device, and distribution of the medical device.

7. The system of claim 5 wherein the RFID tag comprises a sensor to monitor at least one condition of the medical device and to update the stored information when the condition of the medical device changes.

8. The system of claim 5, further comprising a reader configured to interrogate the RFID tag and to receive and store the information transmitted by the RFID tag.

9. The system of claim 5, further comprising at least one of an audible display and a visual display configured to display information stored on the RFID tag.

10. A device for remote radio frequency (RF) interrogation of a prescription drug having a Radio Frequency Identification (RFID) tag associated therewith, the device comprising:

an RFID reader for monitoring prescription drug use, the reader configured for use in facilities where the prescription drug is stored, dispensed, and used, the reader further configured to interrogate tagged prescription drug containers and to receive information therefrom regarding the condition of the prescription drug.

11. The device of claim 10 wherein the reader is configured to receive information regarding the user of the prescription drug.

12. The device of claim 10 wherein the reader is configured to receive information regarding the facility where the prescription drug is stored, dispensed, and used.

13. The device of claim 10 wherein the reader is configured to receive information regarding the condition of a container in which the prescription drug is stored.

14. The device of claim 10 wherein the reader is configured to receive information regarding the location of the prescription drug, the access to the prescription drug, and environmental conditions of the prescription drug.

15. A monitoring system, comprising:
at least one medical device having at least one Radio Frequency Identification (RFID) tag associated therewith; and
a reader configured for real time monitoring on at least a periodic basis of the at least one tag and receiving information from the at least one tag regarding at least one from among the manufacture(?), inventory, sale, delivery, status, and use of the medical device.

16. The system of claim 15 wherein the RFID tag and RFID reader are configured to initiate a transfer of money from one party to another in response to a condition of the medical device.

17. The prescription drug container, comprising:
a receptacle having an openable lid;
a detection device to detect a condition of the lid; and
a tag associated with the receptacle and coupled to the detection device and configured to respond to interrogation and transmit the condition of the lid.

18. The container of claim 17 wherein the detection device comprises a capacitive element formed in the lid and the receptacle.

19. The container of claim 17 wherein the capacitive element comprises a first conductive element formed in the lid and a second conductive element formed in the receptacle so that when the lid is placed on the receptacle, the first and second conductive elements form a capacitive element.

20. A system for the remote, automated monitoring of drug usage, comprising:

- a container for storing the drug, the container having an openable access point thereto;

- a tag formed on the container and configured to detect the condition of the openable access point; and

- a reader configured to interrogate the tag and to receive the information about the condition of the openable access point, the condition comprising at least one from among a location, container movement, opening of the openable access point, and breaking of a seal associated with the openable access point, and a remaining life of a prescription drug in the container, and the condition of the life of the prescription drug in the container.


21. A medical prescription system, comprising:

- a container for storing the prescription; and

- a tag associated with the container and configured with information regarding the prescription.

22. The system of claim 21, wherein the tag is configured with information regarding at least one of patient history, insurance, patient identification, hospital information, dosage, biometrics, government regulation, and physician information.

1/3

*Fig. 1*




Fig. 2

3/3




Fig. 3A




Fig. 3B




Fig. 3C




Fig. 3D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/22074

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G06K19/077 G08B21/02 A61B5/00 A61M37/00 B01L3/00
B65B57/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G06K G08B A61B A61M B01L B65B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 33246 A (TAKEDA NABUO; AHN SUZANNE I (US); HAYS STEVEN R (US); AHN SAMUEL S) 8 June 2000 (2000-06-08) page 3-6 page 8, line 11 - line 22 page 10, line 10 - line 15 ---	1-22
X	WO 01 94016 A (GLAXO GROUP LTD; BIDDLECOMBE ROBERT ANTHONY (GB); VEITCH JEFFREY D) 13 December 2001 (2001-12-13) page 2, line 29 -page 3, line 4 page 10, line 21 -page 14, line 24; figures ---	1-22
X	US 5 963 136 A (O'BRIEN CHARLES TERRENCE) 5 October 1999 (1999-10-05) the whole document --- -/--	1-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 October 2003

Date of mailing of the international search report

06/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Heusler, N

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/22074

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 63368 A (BONNEY STANLEY GEORGE; GODFREY JAMES WILLIAM (GB); GLAXO GROUP LTD) 30 August 2001 (2001-08-30) page 1 -page 2 page 13, line 26 - line 31 ---	1-22
X	WO 02 21425 A (ABRAMS ROBERT S; CAPITOL VIAL INC (US)) 14 March 2002 (2002-03-14) claim 1 ---	1-22
X	US 5 771 657 A (RICE DENNIS WAYNE ET AL) 30 June 1998 (1998-06-30) column 1, line 1 -column 2, line 64 column 5, line 13 - line 37 ---	1-22
X	EP 0 875 292 A (SGT EXPLOITATIE BV) 4 November 1998 (1998-11-04) column 1, line 3 - line 54 ---	1-22
X	US 2002/013614 A1 (THOMPSON DAVID L) 31 January 2002 (2002-01-31) paragraphs '0002!', '0003!', '0009!', '0040!', '0041!', '0047!; figures 1,2,4 ---	1-9
X	US 5 977 431 A (KNAPP TERRY R ET AL) 2 November 1999 (1999-11-02) column 1, line 52 - line 56 column 4, line 6 - line 8 column 4, line 22 - line 40 ---	1-9
X	US 5 423 334 A (JORDAN GUY J) 13 June 1995 (1995-06-13) abstract column 1, line 6 - line 16 column 6, line 45 - line 49 column 7, line 43 - line 44 column 13, line 27 - line 41 ---	1-9
A	US 4 673 932 A (GABRIEL KAIGHAM J ET AL) 16 June 1987 (1987-06-16) column 1, line 20 ---	1-22
X,P	US 2002/188259 A1 (HICKLE RANDALL S ET AL) 12 December 2002 (2002-12-12) abstract paragraphs '0001!', '0009!', '0010!', '0026!'-'0030!; figures 1-3,8 ---	1-22
X,P	DE 101 12 303 A (SIEMENS AG) 2 October 2002 (2002-10-02) paragraphs '0012!', '0057!'-'0059!; claims; figures -----	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/22074

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0033246	A	08-06-2000	AU 1832800 A WO 0033246 A1	19-06-2000 08-06-2000
WO 0194016	A	13-12-2001	AU 1358002 A WO 0194016 A1 EP 1286775 A1	17-12-2001 13-12-2001 05-03-2003
US 5963136	A	05-10-1999	AU 4982199 A CA 2306998 A1 EP 1023711 A1 TW 439048 B WO 0004521 A1 US 6150942 A	07-02-2000 27-01-2000 02-08-2000 07-06-2001 27-01-2000 21-11-2000
WO 0163368	A	30-08-2001	AU 4242801 A WO 0163368 A2 EP 1272907 A2 JP 2003524250 T US 2003023337 A1	03-09-2001 30-08-2001 08-01-2003 12-08-2003 30-01-2003
WO 0221425	A	14-03-2002	AU 8879901 A EP 1337959 A2 WO 0221425 A2 US 2003174046 A1	22-03-2002 27-08-2003 14-03-2002 18-09-2003
US 5771657	A	30-06-1998	NONE	
EP 0875292	A	04-11-1998	NL 1005914 C2 EP 0875292 A1 JP 10332545 A US 6475443 B1 US 2003017082 A1	29-10-1998 04-11-1998 18-12-1998 05-11-2002 23-01-2003
US 2002013614	A1	31-01-2002	EP 1296744 A2 WO 0197907 A2	02-04-2003 27-12-2001
US 5977431	A	02-11-1999	US 5716407 A US 5674288 A US 5300120 A AU 4730096 A WO 9622058 A1 US 5855609 A US 5725578 A AT 189375 T AU 674022 B2 AU 5003093 A BR 9306947 A CA 2142995 A1 DE 69327802 D1 DE 69327802 T2 EP 0703760 A1 JP 8501956 T WO 9404094 A1	10-02-1998 07-10-1997 05-04-1994 07-08-1996 25-07-1996 05-01-1999 10-03-1998 15-02-2000 05-12-1996 15-03-1994 12-01-1999 03-03-1994 09-03-2000 12-10-2000 03-04-1996 05-03-1996 03-03-1994
US 5423334	A	13-06-1995	CA 2114467 A1 EP 0619101 A1 JP 6296633 A	02-08-1994 12-10-1994 25-10-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/22074

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4673932	A	16-06-1987	AU	615486 B2	03-10-1991
			AU	2415688 A	27-01-1989
			AU	577814 B2	06-10-1988
			AU	3712784 A	04-07-1985
			CA	1251273 A1	14-03-1989
			CA	1277748 C2	11-12-1990
			DE	3447599 A1	12-09-1985
			FR	2557714 A1	05-07-1985
			GB	2152335 A ,B	31-07-1985
			GB	2191368 A ,B	09-12-1987
			JP	60215275 A	28-10-1985
			US	4862160 A	29-08-1989
			ZA	8409989 A	30-04-1986

US 2002188259	A1	12-12-2002	WO	02095675 A1	28-11-2002

DE 10112303	A	02-10-2002	DE	10112303 A1	02-10-2002
